Navigation Links
Bacterin to Present at 4th Annual LD MICRO Conference on December 8, 2011
Date:11/22/2011

BELGRADE, Mont., Nov. 22, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at LD MICRO's 4th Annual Conference on December 8, 2011. The conference will be held at the Luxe Hotel in Los Angeles.

Bacterin's chairman and CEO, Guy Cook, is scheduled to present on Thursday, December 8, 2011 at 10:30 a.m. Pacific time, with one-on-one meetings held throughout the day. Management will discuss Bacterin's recent quarterly results, as well as the company's business plan and objectives for the remainder of 2011.

Bacterin reported record revenue of $7.5 million in the third quarter 2011, up 80% year-over-year. For 2012, management expects revenue of $53 million to $56 million.

The LD MICRO Conference brings together 101 presenting companies with more than 150 institutions focused on investing in small and micro cap companies across multiple industries.

About LD MICRO

LD MICRO is a by-invitation only newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks as well as comprehensive reports on select companies throughout the year. LD MICRO concentrates on finding, researching, and investing in companies that are overlooked by institutional investors. It is a non-registered investment advisor. For more information on the list of presenting companies or to register for the event, please visit www.ldmicro.com or call +1-408-457-1042.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Important Cautions Regarding Forward-looking Statements

This news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com


'/>"/>
SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin to Present at Sixth Annual Singular Research Best of the Uncovereds Conference on October 26, 2011
2. Bacterin Awarded Approved Vendor Status for American Medical Concepts Network of Hospitals in the Northwest U.S.
3. Bacterin International Sets Third Quarter 2011 Conference Call for Thursday, November 10, 2011 at 4:30 p.m. ET
4. Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
5. Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter
6. Bacterin Secures $15 Million Credit Facility with MidCap Financial and Silicon Valley Bank
7. Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET
8. Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes
9. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
10. Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results
11. Bacterin International Holdings Launches Third Biologic Scaffold
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- MedDay, a biotechnology company focused on the ... entitled "High doses of biotin in progressive multiple sclerosis: extension ... Professor Ayman Tourbah , Principal Investigator of the Phase ... of Neurology (EAN) in Copenhagen, Denmark . ... place on Sunday, 29 May 2016 from 14:45 to 16:15 ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)...   , Study met both ... superiority in , Excellent plus Good ... of the ascending colon   , ... today announced new positive data from the phase III MORA study ... 2 litre PEG with ascorbate. The study met both primary endpoints ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to ... Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final ... and levels of the game, Connor Sports has committed to a significantly increased focus ...
(Date:5/26/2016)... Pompano Beach, Florida (PRWEB) , ... May 26, 2016 , ... ... Green House® Project offering a new model of care for living and ... on three core values: Meaningful Life in a Real Home provided by Empowered Staff. ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are nearly 14.5 ... 32 million cancer survivors worldwide. On Sunday, June 5, 2016, communities around the world ... Cancer Survivors Day®. , National Cancer Survivors Day® is an annual worldwide Celebration ...
(Date:5/26/2016)... ... 26, 2016 , ... Catalent Pharma Solutions, the leading global ... and global clinical supply services, today announced two key appointments and the opening ... and strategic growth plans in the Asia Pacific region. , Howard Kim has ...
Breaking Medicine News(10 mins):